Krsnaa Diagnostics growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+7.8%	+16.6%
EBITDA	+11.4%	+20.1%
Net Income	+30.7%	+17.8%
EPS (adj.)	+30.7%	+17.8%
Total Assets	+42.3%	+26.1%
Total Equity	+11.1%	+9.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KRSNAA₹496.45

Krsnaa Diagnostics Limited

· Pharma & Health

₹ CrorePeersSURAKSHA HEALTHX NEPHROPLUS 3BBLACKBIOMcap ₹1,610 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+7.8	+16.6
EBITDA	+11.4	+20.1
Net Income	+30.7	+17.8
EPS (adj.)	+30.7	+17.8
Total Assets	+42.3	+26.1
Total Equity	+11.1	+9.9

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.